Feng-Hou Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Feng-Hou Gao has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Chao Zhang
Department of Geriatrics, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 shared publicationsShan-Ling Liu
Department of Clinical Laboratory, The First Hospital of Changsha City,Changsha, Hunan, China
7 shared publicationsJia-Hui Guo
Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oncol, 280 Mohe Rd, Shanghai 201900, Peoples R China
6 shared publications- Feng Liu
Department of Oncology, Shanghai 9th People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
5 shared publications - Quan-Wu Zhang
Department of Pathology Zhengzhou Central Hospital Affiliated to Zhengzhou University Zhengzhou China
4 shared publications Zhen Liu
Department of Clinical Laboratory, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 35 (1) , 1-20
Metabolic reprogramming of myeloid‑derived suppressor cells in colorectal cancer: Mechanistic insights and immunometabolic targeted rehabilitation (Review)
Metabolic reprogramming of myeloid‑derived suppressor cells (MDSCs) plays a role in immunotherapy resistance in colorectal cancer (CRC). This metabolic reprogramming appears to be coordinated by oncogenic mutations (such as adenomatous polyposis coli, KRAS and TP53) through a proposed self‑reinforcing ‘mutation‑metabolism‑suppression’ axis. In the present review, four core metabolic pillars sustaining MDSC pathogenicity and the epimetabolic regulation that durably locks them into a suppressive state were examined. Furthermore, two emerging dimensions were highlighted: The spatial metabolic antagonism through which MDSCs may construct a metabolically hostile zone to limit the functional activity of tertiary lymphoid structures, and the remote manipulation of MDSC function by gut and intratumoral microbiota‑derived metabolites. To transcend the limitations of non‑specific myeloid depletion, immunometabolic rehabilitation is proposed as a potentially transformative framework targeting intrinsic metabolic vulnerabilities to functionally reprogram MDSCs from an immunosuppressive to a homeostatic or immunostimulatory phenotype. By integrating emerging spatial omics for precise target validation, artificial intelligence‑guided rational drug design and microbiome modulation, this paradigm provides a strategic roadmap for next‑generation precision immunotherapy, aiming to achieve durable responses across both microsatellite stable and microsatellite instability‑high CRC.
- 3 November 2026
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 35 (1) , 1-20
Open AccessMetabolic reprogramming of myeloid‑derived suppressor cells in colorectal cancer: Mechanistic insights and immunometabolic targeted rehabilitation (Review)
Metabolic reprogramming of myeloid‑derived suppressor cells (MDSCs) plays a role in immunotherapy resistance in colorectal cancer (CRC). This metabolic reprogramming appears to be coordinated by oncogenic mutations (such as adenomatous polyposis coli, KRAS and TP53) through a proposed self‑reinforcing ‘mutation‑metabolism‑suppression’ axis. In the present review, four core metabolic pillars sustaining MDSC pathogenicity and the epimetabolic regulation that durably locks them into a suppressive state were examined. Furthermore, two emerging dimensions were highlighted: The spatial metabolic antagonism through which MDSCs may construct a metabolically hostile zone to limit the functional activity of tertiary lymphoid structures, and the remote manipulation of MDSC function by gut and intratumoral microbiota‑derived metabolites. To transcend the limitations of non‑specific myeloid depletion, immunometabolic rehabilitation is proposed as a potentially transformative framework targeting intrinsic metabolic vulnerabilities to functionally reprogram MDSCs from an immunosuppressive to a homeostatic or immunostimulatory phenotype. By integrating emerging spatial omics for precise target validation, artificial intelligence‑guided rational drug design and microbiome modulation, this paradigm provides a strategic roadmap for next‑generation precision immunotherapy, aiming to achieve durable responses across both microsatellite stable and microsatellite instability‑high CRC.
- 25 April 2026
- Published by Springer Nature in Cell Death & Differentiation
Endothelial USP2a-METTL16 loop potentiates IL-6 signaling via m6A-mediated IL-6R stabilization in pulmonary vascular remodeling
Dysfunction of vascular endothelial cells is recognized as a critical driver in pulmonary vascular remodeling of pulmonary hypertension (PH). Although interleukin-6 (IL-6) has been firmly established as an indispensable factor leading to pulmonary vascular remodeling, its downstream molecular mechanisms remain incompletely elucidated. Here, we discover that ubiquitin-specific protease 2a (USP2a) is upregulated in lung tissues of PH patients and preclinical PH models, and in IL-6-stimulated endothelial cells. Both the endothelial cell-specific Usp2a genetic deletion and the pharmacological inhibition of USP2a with the inhibitor ML364 alleviate experimental PH manifestations. Mechanistically, USP2a attenuates the degradation of methyltransferase-like 16 (METTL16) by deubiquitination. Notably, METTL16 reciprocally enhances USP2a expression via interactions with eIF3a and eIF3b in a methyltransferase activity-independent manner, establishing a self-reinforcing USP2a-METTL16 regulatory loop. Subsequent investigations reveal that METTL16 enhances N6-methyladenosine (m6A)-mediated IL-6 receptor (IL-6R) mRNA stabilization, thereby promoting the expression of IL-6R. This study demonstrates that endothelial USP2a-METTL16 loop potentiates IL-6 signaling via IL-6R and represents a promising therapeutic target for PH.
- 25 April 2026
- Published by Springer Nature in Cell Death & Differentiation
Endothelial USP2a-METTL16 loop potentiates IL-6 signaling via m6A-mediated IL-6R stabilization in pulmonary vascular remodeling
Dysfunction of vascular endothelial cells is recognized as a critical driver in pulmonary vascular remodeling of pulmonary hypertension (PH). Although interleukin-6 (IL-6) has been firmly established as an indispensable factor leading to pulmonary vascular remodeling, its downstream molecular mechanisms remain incompletely elucidated. Here, we discover that ubiquitin-specific protease 2a (USP2a) is upregulated in lung tissues of PH patients and preclinical PH models, and in IL-6-stimulated endothelial cells. Both the endothelial cell-specific Usp2a genetic deletion and the pharmacological inhibition of USP2a with the inhibitor ML364 alleviate experimental PH manifestations. Mechanistically, USP2a attenuates the degradation of methyltransferase-like 16 (METTL16) by deubiquitination. Notably, METTL16 reciprocally enhances USP2a expression via interactions with eIF3a and eIF3b in a methyltransferase activity-independent manner, establishing a self-reinforcing USP2a-METTL16 regulatory loop. Subsequent investigations reveal that METTL16 enhances N6-methyladenosine (m6A)-mediated IL-6 receptor (IL-6R) mRNA stabilization, thereby promoting the expression of IL-6R. This study demonstrates that endothelial USP2a-METTL16 loop potentiates IL-6 signaling via IL-6R and represents a promising therapeutic target for PH.
- Open Access
- 24 April 2026
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (6) , 1-14
Therapeutic potential of tertiary lymphoid structures in breast cancer (Review)
Tertiary lymphoid structures (TLS) are organized immune aggregates within the tumor microenvironment that are associated with improved prognosis and immunotherapy response in breast cancer, yet their functional duality and therapeutic potential require further clarification. The present review comprehensively summarizes current knowledge on TLS in breast cancer, focusing on their molecular mechanisms of formation and maturation, multifaceted functions in anti‑tumor immunity, established prognostic importance and emerging strategies for therapeutic targeting. The present study highlights that mature and functional TLS are key mediators of adaptive anti‑tumor immunity, whereas immature TLS may have opposing effects. Their presence and characteristics hold strong prognostic value and can predict response to immune checkpoint inhibitors. Consequently, therapeutic strategies aimed at inducing or enhancing TLS represent a promising direction for breast cancer immunotherapy. However, further research is needed to elucidate the precise regulatory networks and translate TLS‑focused strategies into clinical practice.
- 24 April 2026
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (6) , 1-14
Open AccessTherapeutic potential of tertiary lymphoid structures in breast cancer (Review)
Tertiary lymphoid structures (TLS) are organized immune aggregates within the tumor microenvironment that are associated with improved prognosis and immunotherapy response in breast cancer, yet their functional duality and therapeutic potential require further clarification. The present review comprehensively summarizes current knowledge on TLS in breast cancer, focusing on their molecular mechanisms of formation and maturation, multifaceted functions in anti‑tumor immunity, established prognostic importance and emerging strategies for therapeutic targeting. The present study highlights that mature and functional TLS are key mediators of adaptive anti‑tumor immunity, whereas immature TLS may have opposing effects. Their presence and characteristics hold strong prognostic value and can predict response to immune checkpoint inhibitors. Consequently, therapeutic strategies aimed at inducing or enhancing TLS represent a promising direction for breast cancer immunotherapy. However, further research is needed to elucidate the precise regulatory networks and translate TLS‑focused strategies into clinical practice.
- Open Access
- 1 August 2024
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 25 (1) , 2385517
Autophagic degradation of CDK4 is responsible for G0/G1 cell cycle arrest in NVP-BEZ235-treated neuroblastoma
CDK4 is highly expressed and associated with poor prognosis and decreased survival in advanced neuroblastoma (NB). Targeting CDK4 degradation presents a potentially promising therapeutic strategy compared to conventional CDK4 inhibitors. However, the autophagic degradation of the CDK4 protein and its anti-proliferation effect in NB cells has not been mentioned. We identified autophagy as a new pathway for the degradation of CDK4. Firstly, autophagic degradation of CDK4 is critical for NVP-BEZ235-induced G0/G1 arrest, as demonstrated by the overexpression of CDK4, autophagy inhibition, and blockade of autophagy-related genes. Secondly, we present the first evidence that p62 binds to CDK4 and then enters the autophagy-lysosome to degrade CDK4 in a CTSB-dependent manner in NVP-BEZ235 treated NB cells. Similar results regarding the interaction between p62 and CDK4 were observed in the NVP-BEZ235 treated NB xenograft mouse model. Autophagic degradation of CDK4 plays a pivotal role in G0/G1 cell cycle arrest in NB cells treated with NVP-BEZ235.
- 1 August 2024
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 25 (1) , 2385517
Open AccessAutophagic degradation of CDK4 is responsible for G0/G1 cell cycle arrest in NVP-BEZ235-treated neuroblastoma
CDK4 is highly expressed and associated with poor prognosis and decreased survival in advanced neuroblastoma (NB). Targeting CDK4 degradation presents a potentially promising therapeutic strategy compared to conventional CDK4 inhibitors. However, the autophagic degradation of the CDK4 protein and its anti-proliferation effect in NB cells has not been mentioned. We identified autophagy as a new pathway for the degradation of CDK4. Firstly, autophagic degradation of CDK4 is critical for NVP-BEZ235-induced G0/G1 arrest, as demonstrated by the overexpression of CDK4, autophagy inhibition, and blockade of autophagy-related genes. Secondly, we present the first evidence that p62 binds to CDK4 and then enters the autophagy-lysosome to degrade CDK4 in a CTSB-dependent manner in NVP-BEZ235 treated NB cells. Similar results regarding the interaction between p62 and CDK4 were observed in the NVP-BEZ235 treated NB xenograft mouse model. Autophagic degradation of CDK4 plays a pivotal role in G0/G1 cell cycle arrest in NB cells treated with NVP-BEZ235.
- Open Access
- 11 May 2023
- Published by Springer Nature in Research Square
Autophagic degradation of CDK4 is responsible for G0/G1 cell cycle arrest in NVP-BEZ235-treated neuroblastoma
CDK4 is highly expressed and correlated with poor prognosis and decreased survival in advanced NB. Seeking a regimen that selectively targets CDK4 degradation is a potentially promising therapeutic strategy relative to conventional CDK4 inhibitors.In this work, we determined that autophagy as a new pathway for the degradation of CDK4. Firstly, autophagic degradation of CDK4 is critical for NVP-BEZ235-induced G0/G1 arrest and growth inhibition via the blockade of autophagy-related gene Beclin1. Secondly, we observed the first evidence that the p62 binds to CDK4 and then enter autophagolysosome to degradate CDK4 in a CTSB-dependent manner in NVP-BEZ235 treated NB cells. Analogous results regarding the interaction p62 with CDK4 were observed in NVP-BEZ235 treated neuroblastoma xenograft mouse model. These results not only established the pivotal role of the autophagy pathway in CDK4 turnover but also suggest the potential application of NVP-BEZ235 or other drugs via the therapeutic modulation of autophagic degradation of CDK4 protein in NB.
- 11 May 2023
- Published by Springer Nature in Research Square
Open AccessAutophagic degradation of CDK4 is responsible for G0/G1 cell cycle arrest in NVP-BEZ235-treated neuroblastoma
CDK4 is highly expressed and correlated with poor prognosis and decreased survival in advanced NB. Seeking a regimen that selectively targets CDK4 degradation is a potentially promising therapeutic strategy relative to conventional CDK4 inhibitors.In this work, we determined that autophagy as a new pathway for the degradation of CDK4. Firstly, autophagic degradation of CDK4 is critical for NVP-BEZ235-induced G0/G1 arrest and growth inhibition via the blockade of autophagy-related gene Beclin1. Secondly, we observed the first evidence that the p62 binds to CDK4 and then enter autophagolysosome to degradate CDK4 in a CTSB-dependent manner in NVP-BEZ235 treated NB cells. Analogous results regarding the interaction p62 with CDK4 were observed in NVP-BEZ235 treated neuroblastoma xenograft mouse model. These results not only established the pivotal role of the autophagy pathway in CDK4 turnover but also suggest the potential application of NVP-BEZ235 or other drugs via the therapeutic modulation of autophagic degradation of CDK4 protein in NB.
- 10 April 2023
- Published by Elsevier in Experimental Cell Research
- Vol. 427 (1) , 113597
Up-regulated oxidized USP2a can increase Mdm2-p60-p53 to promote cell apoptosis
- 10 April 2023
- Published by Elsevier in Experimental Cell Research
- Vol. 427 (1) , 113597
Up-regulated oxidized USP2a can increase Mdm2-p60-p53 to promote cell apoptosis
- 15 August 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 627, 5-11
P62/SQSTM1 mediates the autophagy-lysosome degradation of CDK2 protein undergoing PI3Kα/AKT T308 inhibition
- 15 August 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 627, 5-11
P62/SQSTM1 mediates the autophagy-lysosome degradation of CDK2 protein undergoing PI3Kα/AKT T308 inhibition
- Open Access
- 1 July 2022
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 11 (7) , 2388-2397
Immature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice
Original Article Immature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice Shanshan Yin, Chao Zhang, Fenghou Gao
- 1 July 2022
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 11 (7) , 2388-2397
Open AccessImmature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice
Original Article Immature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice Shanshan Yin, Chao Zhang, Fenghou Gao
- Open Access
- 1 January 2022
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 18 (6) , 2515-2526
IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma
Rationale: In multiple myeloma (MM), the activities of non-homologous end joining (NHEJ) and homologous recombination repair (HR) are increased compared with healthy controls. Whether and how IKZF1 as an enhancer of MM participates in the DNA repair pathway of tumor cells remains elusive.
- 1 January 2022
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 18 (6) , 2515-2526
Open AccessIKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma
Rationale: In multiple myeloma (MM), the activities of non-homologous end joining (NHEJ) and homologous recombination repair (HR) are increased compared with healthy controls. Whether and how IKZF1 as an enhancer of MM participates in the DNA repair pathway of tumor cells remains elusive.
- Open Access
- 1 May 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (10) , 857
Tumor microenvironment immune-related lncRNA signature for patients with melanoma
Background: The incidence of malignant melanoma accounts for only approximately 5% of skin malignant tumors, however, it accounts for 75% of its mortality. Long-chain non-coding RNA (lncRNA) has a wide range of functional activities. Disorders of lncRNAs may lead to the occurrence and development of melanoma, and may also be related to immunotherapy. Methods: The transcriptomic data of primary and metastatic melanoma patients and 331 immune-related genes were downloaded from skin cutaneous melanoma (SKCM) in the The Cancer Genome Atlas (TCGA) database. On this basis, 460 immunologically relevant lncRNAs were identified by constructing a co-expression network of immunogenic genes and lncRNAs in primary and metastatic melanoma patients. Prognostic genes were screened using univariate Cox regression analysis. ROC analysis was performed to evaluate the robustness of the prognostic signature. Results: Univariate correlation analysis showed that only 3 of the 23 immune-related lncRNAs were at high risk and the rest were at low risk. Signatures of 7 immune-related lncRNAs were identified by multivariate correlation analysis. The clinical correlation analysis showed that the 7 immune-related lncRNAs were associated with the clinical stage of primary and metastatic melanoma. Principal component analysis (PCA) showed that only 7 immune-related lncRNA signals divided tumor patients into high-risk and low-risk groups, while the low-risk group was enriched in the immune system process M13664 and immune response M19817 sets. PPI interaction network analysis showed that 11 G protein-coupled receptors and 6 corresponding ligands in the 2 gene sets affected the tumor microenvironment and were negatively related to the risk of the 7 immune-related lncRNAs. The tumor microenvironment immune cell infiltration analysis also supported the finding that anti-tumor immunity in the low-risk group was stronger than in the high-risk group. Conclusions: These results indicate that characteristics of the 7 immune-related lncRNAs have prognostic value for melanoma patients and can be used as potential immunotherapy targets.
- 1 May 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (10) , 857
Open AccessTumor microenvironment immune-related lncRNA signature for patients with melanoma
Background: The incidence of malignant melanoma accounts for only approximately 5% of skin malignant tumors, however, it accounts for 75% of its mortality. Long-chain non-coding RNA (lncRNA) has a wide range of functional activities. Disorders of lncRNAs may lead to the occurrence and development of melanoma, and may also be related to immunotherapy. Methods: The transcriptomic data of primary and metastatic melanoma patients and 331 immune-related genes were downloaded from skin cutaneous melanoma (SKCM) in the The Cancer Genome Atlas (TCGA) database. On this basis, 460 immunologically relevant lncRNAs were identified by constructing a co-expression network of immunogenic genes and lncRNAs in primary and metastatic melanoma patients. Prognostic genes were screened using univariate Cox regression analysis. ROC analysis was performed to evaluate the robustness of the prognostic signature. Results: Univariate correlation analysis showed that only 3 of the 23 immune-related lncRNAs were at high risk and the rest were at low risk. Signatures of 7 immune-related lncRNAs were identified by multivariate correlation analysis. The clinical correlation analysis showed that the 7 immune-related lncRNAs were associated with the clinical stage of primary and metastatic melanoma. Principal component analysis (PCA) showed that only 7 immune-related lncRNA signals divided tumor patients into high-risk and low-risk groups, while the low-risk group was enriched in the immune system process M13664 and immune response M19817 sets. PPI interaction network analysis showed that 11 G protein-coupled receptors and 6 corresponding ligands in the 2 gene sets affected the tumor microenvironment and were negatively related to the risk of the 7 immune-related lncRNAs. The tumor microenvironment immune cell infiltration analysis also supported the finding that anti-tumor immunity in the low-risk group was stronger than in the high-risk group. Conclusions: These results indicate that characteristics of the 7 immune-related lncRNAs have prognostic value for melanoma patients and can be used as potential immunotherapy targets.